For example, the use of celecoxib (a selective COX-2 inhibitor) as an adjuvant to chemotherapy significantly improved the overall survival and disease-free survival in COX-2-positive gastric cancer patients [128], and its oral administration significantly improved responses in patients with recurrent ovarian cancer characterized by platinum-based drug resistance (phase II, NCT01124435) [129]. The gene discussed is PTGS2; the disease is ovarian cancer.